Skip to main content
Premium Trial:

Request an Annual Quote

Arena to Evaluate Atugen s Antisense Technology

NEW YORK, Sept 10 – Atugen, a Berlin-based functional genomics company, said Monday that Arena Pharmaceuticals had agreed to evaluate its G-protein coupled receptor technology.

Under the terms of the deal, Atugen’s US-based subsidiary will receive central nervous system gene targets from Arena for evaluation using its GeneBlocs gene expression technologies. The company will then try to determine gene function in vivo.

"We are well aware of the contribution antisense oligonucleotide approaches have made to the validation of peripheral drug targets," Martin Gore, a senior scientist at Arena, said in a statement.

"We hope that this technology validation study will uncover the general utility of antisense oligonucleotide technologies, particularly Atugen's proprietary GeneBloc technology, for CNS target validation,” he added. 

Based in San Diego, Arena is mainly focused on finding and developing new drugs that act on G protein-coupled receptors. 

Atugen said that unlike knockout technology, its “knockdown” methodology allows researchers to reduce expression of specific genes in designated cells. The company added that this provides a highly selective and low toxicity way of evaluating gene expression. Plus, Atugen said that its technology can be used after the genes have been developed in utero, reducing the number of false positives that occur in knockout systems.

“Atugen's technology overcomes the problems associated with in vivo target validation using 'target knockouts,’ which result in the total inhibition of gene function from embryo to adult,” the company said in a statement.
The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.